$1.7 Billion Deal: AbbVie Licenses FutureGen's Preclinical TL1A Antibody to Strengthen Autoimmune Portfolio

Jun 14, 2024 16:52 CST Updated 16:52

AbbVie

Innovative Drug Developer

Source: Medical Notes

On June 13, Mingji Biologics announced the global rights transfer of its preclinical TL1A antibody to AbbVie, with AbbVie making the payment.$150 million upfront paymentAnd recent milestone payments, as well as$1.56 Billion in Milestone Payments, Double-Digit Percentage of Sales Royalties。

FG-M701 is the first autoimmune pipeline from Mingji Biotech, achieving higher efficacy and reduced dosing frequency through engineered modifications.

Summary

In recent years, novel autoimmune drugs have been an absolute hotspot in the U.S. market, with high-value deals occurring continuously. The TL1A field has already seen multiple transactions, including Merck's $10.8 billion acquisition of Prometheus, Roche's $7.25 billion acquisition of Telavant, Sanofi's $1.5 billion licensing of Teva’s TL1A antibody, and AbbVie's $1.7 billion licensing of Mabwell’s TL1A antibody. This transaction between Mabwell and AbbVie also marks the beginning of China-produced autoimmune drugs going global, and subsequently, more innovative China-produced autoimmune drugs may enter the international market.

· END ·

--Featured Recommendations--